Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813
Int J Radiat Oncol Biol Phys
.
2020 Dec 1;108(5):1399.
doi: 10.1016/j.ijrobp.2020.09.021.
Epub 2020 Nov 18.
Authors
J L Fleming
1
,
S Pugh
2
,
E H Bell
3
,
S M Chang
4
,
J McElroy
1
,
A Becker
1
,
C D Timmers
5
,
H A Shih
6
,
L Ashby
7
,
G K Hunter
8
,
J P Bahary
9
,
C J Schultz
10
,
B D Kavanagh
11
,
W A Yung
12
,
I Robins
13
,
M Werner-Wasik
14
,
A Chakravarti
1
Affiliations
1
The Ohio State University, Columbus, OH.
2
NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
3
Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH.
4
University of California San Francisco Medical Center-Mount Zion, San Francisco, CA.
5
Medical University of South Carolina, Charleston, SC.
6
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
7
Arizona Oncology Services Foundation, Tucson, AZ.
8
Intermountain Medical Center, Murray, UT.
9
Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada.
10
(10)Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
11
(11)University of Colorado Denver, Denver, CO.
12
(12)University of Texas-MD Anderson Cancer Center, Houston, TX.
13
(13)University of Wisconsin School of Medicine and Public Health, Madison, WI.
14
(14)Thomas Jefferson University Hospital, Philadelphia, PA.
PMID:
33427658
DOI:
10.1016/j.ijrobp.2020.09.021
No abstract available